Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2337
Source ID: NCT00744926
Associated Drug: Placebo
Title: A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: placebo|DRUG: taspoglutide|DRUG: taspoglutide
Outcome Measures: Primary: Absolute change from baseline in HbA1c, 24 weeks | Secondary: Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies., Throughout study|Change from baseline in fasting plasma glucose; change from baseline in body weight., 24 weeks|Responder rates for HbA1c (target <=7.0%, <=6.5%); relative change in glucose, insulin, C-peptide and glucagon during a meal tolerance test; beta cell function., 24 weeks
Sponsor/Collaborators: Sponsor: Hoffmann-La Roche
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 373
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2008-08
Completion Date: 2010-04
Results First Posted:
Last Update Posted: 2016-07-28
Locations: Phoenix, Arizona, 85015, United States|Los Angeles, California, 90057, United States|Santa Ana, California, 92701, United States|Avon, Indiana, 46123, United States|Pahrump, Nevada, 89048, United States|Charlotte, North Carolina, 28211, United States|Greer, South Carolina, 29651, United States|Mount Pleasant, South Carolina, 29464, United States|San Antonio, Texas, 78237, United States|Richmond, Virginia, 23294, United States|Adelaide, 5000, Australia|St. Leonards, 2065, Australia|Guatemala, 01010, Guatemala|Guatemala, 01014, Guatemala|Haifa, 31096, Israel|Haifa, 34162, Israel|Holon, 58100, Israel|Jerusalem, 91200, Israel|Kfar Saba, 44281, Israel|Petach Tikva, 49100, Israel|Tel Aviv, 64239, Israel|Acapulco, 39670, Mexico|Aguascalientes, 20230, Mexico|Chihuahua, 31238, Mexico|Hermosillo, 83200, Mexico|Mexico City, 11650, Mexico|Morelia, 58000, Mexico|Lima, Lima 33, Peru|San Isidro, 27, Peru|Bucuresti, 020359, Romania|Buzau, 120203, Romania|Cluj-napoca, 400006, Romania|Ploiesti, 100163, Romania|Ploiesti, 100342, Romania|Tg. Mures, 540142, Romania|Chelyabinsk, 454136, Russian Federation|Jaloslave, Russian Federation|Moscow, 109263, Russian Federation|Moscow, 117036, Russian Federation|Moscow, 119048, Russian Federation|Moscow, 129110, Russian Federation|S. Petersburg, 195067, Russian Federation|S.petersburg, 194017, Russian Federation|St. Petersburg, 191124, Russian Federation|Yaroslavl, 150062, Russian Federation|Dolny Kubin, 02601, Slovakia|Levice, 034 01, Slovakia|Presov, 080 01, Slovakia|Trencin, 911 01, Slovakia|Zilina, 010 01, Slovakia|Changhua, 500, Taiwan|Tainan, 710, Taiwan|Taipei, 100, Taiwan|Tapei County, 231, Taiwan|Chernovtsy, 58002, Ukraine|Kiev, 01601, Ukraine|Kiev, 04050, Ukraine|Lviv, 79010, Ukraine
URL: https://clinicaltrials.gov/show/NCT00744926

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress